---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-001630"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T14:20:13.008663+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex doses first patient in Phase 2 expansion of Acclaim-3 trial for Reqorsa + Tecentriq in ES-SCLC

## Summary
- Phase 2 expansion will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week progression-free survival rate.
- Recommended Phase 2 dose of Reqorsa set at 0.12 mg/kg (highest Phase 1 dose), no dose-limiting toxicities observed.
- Interim analysis planned after first 25 patients reach 18 weeks of follow-up; enrollment of initial 25 expected in H2 2025.
- Acclaim-3 holds FDA Fast Track and Orphan Drug Designations for this extensive-stage small cell lung cancer indication.

## SEC filing metadata
- accession: 0001437749-25-001630
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925001630/0001437749-25-001630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925001630/gnpx20241220_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-001630
- JSON: https://secwatch.observer/filing/0001437749-25-001630.json
- Plain text: https://secwatch.observer/filing/0001437749-25-001630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.